SGLT2 Inhibitors and Heart Failure | Harvard Medical School Continuing Education
What benefits can SGLT2 inhibitors provide to heart failure patients?
Dr. Lee-Shing Chang, MD, an endocrinologist at Brigham and Women’s Hospital, reviews the cardiovascular outcomes trials that first indicated the benefit of SGLT2 inhibitors in heart failure patients as well as the current use of SGLT2 inhibitors in heart failure with both reduced and preserved injection fraction (HFrEF and HFpEF). Guidelines for patients with type 2 diabetes are discussed.
00:00 | Introduction
00:42 | Discovery of SGLT2 inhibitors for heart failure
02:50 | Key findings from HFrEF: DAPA-HF trial
04:05 | Key findings from HFrEF: EMPEROR-Reduced trial
04:51 | Key findings from HFpEF: EMPEROR-Preserved trial
06:22 | Discussion of trial applications and guidelines
References:
McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303
Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190
Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038
Notice: At this time, the content in this video is not accredited.
source
Disclaimer: This content including advice provides generic information only. It is in no way a substitute for a qualified medical opinion. Always consult a specialist or your own doctor for more information.
Keywords: [vid_tags]